Group by:
Date |
Item TypeArticle
The CAIRP (CAndesartan for In-stent Restenosis Prevention) trial - A multicenter study of AT1-receptor blocker therapy in coronary stenting.
Kraemer, J., Ruf, R.G., Schmidt, S., Axthelm, C., Strasser, R., Janssen, G., Thieme, T., Kusch, A., Waigand, J., Dietz, R. and Gross, C.M.
Journal of Invasive Cardiology 20
(5): 205-210.
May 2008
Recurrent in-stent restenosis is not associated with the angiotensin-converting enzyme D/I, angiotensinogen Thr174Met and Met235Thr, and the angiotensin-II receptor 1 A1166C polymorphism.
Gross, C.M., Perrot, A., Geier, C., Posch, M.G., Hassfeld, S., Kramer, J., Schmidt, S., Derer, W., Dietz, R. and Oezcelik, C.
Journal of Invasive Cardiology 19
(6): 261-264.
1 June 2007
This list was generated on Sat Dec 21 13:51:00 2024 UTC.